Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRCA1/2”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT05006131
What this trial is testing

Pancreatic Cancer Screening for At-risk Individuals

Who this might be right for
Pancreatic Cancer, Adult
Beth Israel Deaconess Medical Center 1,395
Not applicableUnknownNCT04368442
What this trial is testing

Cohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic Mutation

Who this might be right for
Breast Cancer Metastatic
Samsung Medical Center 583
Early research (Phase 1)Study completedNCT03509636
What this trial is testing

Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer

Who this might be right for
Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd. 113
Early research (Phase 1)Study completedNCT05904730
What this trial is testing

Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations

Who this might be right for
Breast CancerOvarian CancerBreast Neoplasms+5 more
Lynkcell Europe 10
Not applicableNot Yet RecruitingNCT07591532
What this trial is testing

Pregnancy Outcomes After Breast Cancer in Young Women With Germline Pathogenic Variants in Genes Other Than BRCA

Who this might be right for
Breast CancerBreast Cancer and Pregnancy
Jules Bordet Institute 2,200
Early research (Phase 1)Not Yet RecruitingNCT06614751
What this trial is testing

A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway

Who this might be right for
Solid CancersBRCA MutationHRD Cancer+8 more
Danatlas Pharmaceuticals Co., Ltd 112
Not applicableLooking for participantsNCT07292246
What this trial is testing

A Prospective CohorT Study of HandX - Assisted ENdoscopic MAstectomy: Feasibility and Safety (ATHENA I Study)

Who this might be right for
Breast CancerBRCA 1 Gene MutationBRCA 2 Gene Mutation+5 more
Vasileios Kalles 15
Not applicableLooking for participantsNCT06726642
What this trial is testing

CfDNA in Hereditary And High-risk Malignancies 2

Who this might be right for
Hereditary Cancer Syndrome
University Health Network, Toronto 1,000
Testing effectiveness (Phase 2)Ended earlyNCT03565991
What this trial is testing

Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid TumorsGenes, BRCA 1
Pfizer 202
Large-scale testing (Phase 3)UnknownNCT04296370
What this trial is testing

Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Who this might be right for
Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
Jiangsu HengRui Medicine Co., Ltd. 474
Testing effectiveness (Phase 2)Study completedNCT03845296
What this trial is testing

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Who this might be right for
Deleterious BRCA1 Gene MutationDeleterious BRCA2 Gene MutationLoss of Heterozygosity+8 more
SWOG Cancer Research Network 64
Testing effectiveness (Phase 2)Active Not RecruitingNCT03911973
What this trial is testing

Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers

Who this might be right for
TNBC - Triple-Negative Breast Cancer
Kari Wisinski 37
Very early researchEnded earlyNCT03382574
What this trial is testing

Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

Who this might be right for
Ovarian Carcinoma
National Cancer Institute (NCI) 2
Not applicableEnded earlyNCT02341118
What this trial is testing

Capturing BRCA1/2 Mutational Status in Women With High Grade Serous Ovarian Cancer and Impact on Clinical Outcome.

Who this might be right for
Ovarian Cancer
University Health Network, Toronto 109
Not applicableStudy completedNCT03881683
What this trial is testing

Determination of the Feasibility of Tumoural Somatic Mutations Detection in Blood of Patients With Ovarian Cancer

Who this might be right for
Ovarian Cancer
Institut de Cancérologie de Lorraine 24
Not applicableLooking for participantsNCT07197723
What this trial is testing

Study of How People Make Decisions About Prostate Cancer Risk

Who this might be right for
BRCA1/2Geneitic Testing
Memorial Sloan Kettering Cancer Center 150
Testing effectiveness (Phase 2)WithdrawnNCT05672095
What this trial is testing

Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+3 more
City of Hope Medical Center
Not applicableLooking for participantsNCT02478892
What this trial is testing

Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk

Who this might be right for
Pancreatic Cancer
Abramson Cancer Center at Penn Medicine 200
Early research (Phase 1)Study completedNCT02482311
What this trial is testing

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

Who this might be right for
Ovarian Cancer, TNBC, SCLC, Other Solid Tumours
AstraZeneca 92
Testing effectiveness (Phase 2)Active Not RecruitingNCT05033756
What this trial is testing

Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO

Who this might be right for
Malignant Neoplasm of BreastBreast Cancer
Institut fuer Frauengesundheit 11
Next Page